{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:08Z","timestamp":1792512128001,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Neonatal diabetes mellitus (NDM) is a rare disease, the prevalence of which is 1 in 90,000\u2013160,000 live births, with 31% of all preterm diagnoses linked to monogenic causes. NDM is differentiated into transient, permanent, and syndromic NDM. Furthermore, 40% of patients diagnosed with NDM are responsive to oral sulfonylureas (SUs) due to expressed mutations of the ABCC8 or KCNJ11 genes coding for adenosine triphosphate-sensitive potassium channel (KATP) subunits in pancreatic beta (\u03b2) cells. SUs bind to the sulfonylurea receptor 1 subunit, closing the KATP channel and increasing insulin secretion. Although SUs remain the mainstay of NDM treatment, these medications are traditionally only dosed and approved for hyperglycemic control in adults. Current treatment regimens suggest a high dose, 1\u2005mg\/kg\/day, for patients with KCNJ11 neonatal diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>Our male neonate was born at 27\u2005weeks and 1,020\u2005g via emergency cesarean section due to complete placenta previa and maternal hemorrhage following perinatal betamethasone administration. Neonatal resuscitation was required. During resuscitation, the patient was intubated and found to be hyperglycemic. He was subsequently started on Regular Humulin at 0.1\u2005units\/kg\/dose subcutaneously (SQ) and increased to 0.2\u2005units\/kg\/dose SQ before transfer to our facility on day of life (DOL) 19. In our neonatal intensive care unit, the patient was transitioned to an insulin drip due to difficulty obtaining and administering the appropriate, but minuscule, SQ insulin doses. Genetic testing was positive for a pathogenic variant c.679G&amp;gt;A (p.Glu227Lys) in KCNJ11; therefore, glyburide was started at 0.1\u2005mg\/kg\/dose twice a day on DOL 54, resulting in euglycemia. Hyperglycemia recurred after an initial attempt to wean; however, a subsequent wean on DOL 70 was successful in maintaining euglycemia without insulin or glyburide for 48\u2005h prior to discharge on DOL 78.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This case report describes the unique and complicated clinical course of a premature neonate with an initially undifferentiated class of NDM requiring a microdose-based approach, i.e., a fraction of a regular dose, to both insulin and SU-based management. This report offers a concise recount of the applied diagnostic and therapeutic procedures while suggesting a decision tree for future NDM management in neonates.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1456818","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:44Z","timestamp":1744781144000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Challenges of insulin and sulfonylurea dosing in an extremely premature infant for the management of KCNJ11-associated neonatal diabetes mellitus"],"prefix":"10.3389","volume":"13","author":[{"given":"Ishan","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirenkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Garganta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clp.2017.10.006","article-title":"Neonatal diabetes mellitus","volume":"45","author":"Lemelman","year":"2018","journal-title":"Clin Perinatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"540718","DOI":"10.3389\/fped.2020.540718","article-title":"Neonatal diabetes mellitus","volume":"8","author":"Beltrand","year":"2020","journal-title":"Front Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4183\/aeb.2016.157","article-title":"Study of KCNJ11 gene mutations in association with monogenic diabetes of infancy and response to sulfonylurea treatment in a cohort study in Egypt","volume":"12","author":"Madani","year":"2016","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s1056-8727(00)00081-7","article-title":"Tissue-specific effects of sulfonylureas: lessons from studies of cloned KATP channels","volume":"14","author":"Ashcroft","year":"2000","journal-title":"J Diabetes Complicat"},{"key":"B5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1055\/s-2007-979837","article-title":"Mechanisms of the glycaemic effects of sulfonylureas","volume":"28","author":"Ashcroft","year":"1996","journal-title":"Horm Metab Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.18632\/oncotarget.22548","article-title":"Sulfonylurea for the treatment of neonatal diabetes owing to KATP-channel mutations: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"908152","DOI":"10.1155\/2015\/908152","article-title":"KCNJ11: genetic polymorphisms and risk of diabetes mellitus","volume":"2015","author":"Haghvirdizadeh","year":"2015","journal-title":"J Diabetes Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1072078","DOI":"10.3389\/fneur.2023.1072078","article-title":"Case report: neonatal diabetes mellitus caused by KCNJ11 mutation presenting with intracranial hemorrhage","volume":"14","author":"Wu","year":"2023","journal-title":"Front Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e240048","DOI":"10.1530\/edm-24-0048","article-title":"Challenges in diagnosis and treatment of KCNJ11-mody","volume":"2024","author":"Gon\u00e7alves","year":"2024","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"E2709","DOI":"10.1210\/jc.2014-2494","article-title":"Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons","volume":"99","author":"Carmody","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s2213-8587(18)30106-2","article-title":"Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study","volume":"6","author":"Bowman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/dmso.s198932","article-title":"Recent advances in neonatal diabetes","volume":"13","author":"Dahl","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/pedi.13041","article-title":"Neonatal diabetes due to potassium channel mutation: response to sulfonylurea according to the genotype","volume":"21","author":"Garcin","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jcjd.2019.05.002","article-title":"Transient neonatal diabetes: an etiologic clue for the adult diabetologist","volume":"44","author":"Novak","year":"2020","journal-title":"Can J Diabetes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e37423","DOI":"10.1371\/journal.pone.0037423","article-title":"Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene","volume":"7","author":"Bonnefond","year":"2012","journal-title":"PLoS One"},{"key":"B16","article-title":"NM_000525.4(KCNJ11):c.679G>A(p.Glu227Lys)","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.20945\/2359-3997000000484","article-title":"The role of intermittent continuous glucose monitoring in a successful outpatient transition from insulin to glibenclamide in a patient with transient neonatal diabetes","volume":"66","author":"Lyra","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clp.2017.10.006","article-title":"Neonatal diabetes mellitus: an update on diagnosis and management","volume":"45","author":"Lemelman","year":"2018","journal-title":"Clin Perinatol"},{"key":"B19","article-title":"Entry - *600937 - potassium channel, inwardly rectifying, subfamily J, member 11; KCNJ11. OMIM (2020)","author":"Scott","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5863\/1551-6776-16.4.291","article-title":"Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate","volume":"16","author":"Barone","year":"2011","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/nejmoa0803725","article-title":"Early insulin therapy in very-low-birth-weight infants","volume":"359","author":"Beardsall","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1456818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:45Z","timestamp":1744781145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1456818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":21,"alternative-id":["10.3389\/fped.2025.1456818"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1456818","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1456818"}}